# PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib

> **NCT02389842** · PHASE1 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 79 (actual)

## Conditions studied

- Advanced Solid Tumours
- Breast Cancer

## Interventions

- **DRUG:** Palbociclib + Taselisib / Pictilisib

## Key facts

- **NCT ID:** NCT02389842
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-25
- **Primary completion:** 2018-10-31
- **Final completion:** 2021-05-26
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2024-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389842, "PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02389842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*